Pfizer signs $5.3 billion Covid-19 pill deal with US govt
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Saturday
January 28, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SATURDAY, JANUARY 28, 2023
Pfizer signs $5.3 billion Covid-19 pill deal with US govt

Coronavirus chronicle

Reuters
19 November, 2021, 10:35 am
Last modified: 19 November, 2021, 10:38 am

Related News

  • Democratic senators call for ban on marketing guns to kids
  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • Classified documents found at former US Vice President Pence's home
  • US reiterates support for Finland, Sweden joining NATO
  • US, Germany poised to send tanks to Ukraine, answering Kyiv's pleas

Pfizer signs $5.3 billion Covid-19 pill deal with US govt

The oral drug could be a promising new weapon in the fight against the pandemic, as it can be taken as an early at-home treatment to help prevent Covid-19 hospitalisations and deaths.

Reuters
19 November, 2021, 10:35 am
Last modified: 19 November, 2021, 10:38 am
 A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Photo :Reuters
A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Photo :Reuters

Pfizer Inc has signed a $5.29 billion deal with the US government to deliver 10 million courses of its Covid-19 oral antiviral drug starting this year, the drugmaker said on Thursday.

The oral drug could be a promising new weapon in the fight against the pandemic, as it can be taken as an early at-home treatment to help prevent Covid-19 hospitalisations and deaths.

Pfizer on Tuesday filed for US authorisation of the drug, Paxlovid, and said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.

"This promising treatment could help accelerate our path out of this pandemic by offering another life-saving tool for people who get sick with Covid-19," said Xavier Becerra, secretary of the United States Department of Health and Human Services.

The company earlier this month said the drug cut by 89 percent the chance of hospitalisation or death for adults at risk of severe disease.

The trial's results suggest that Pfizer's drug surpasses Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the chance of dying or being hospitalized for Covid-19 patients at high risk of serious illness.

The US government has also signed a contract worth $2.2 billion for courses of the Merck drug.

World+Biz / USA

Pfizer / USA

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Bloomberg
    India state insurer doubles down on Adani amid short seller row
  • The Bombay blood type: A rare blood group in urgent need of database
    The Bombay blood type: A rare blood group in urgent need of database
  • Photo: TBS
    TBS Roundtable: What lies ahead in 2023

MOST VIEWED

  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent
  • Sean Bagley, 14, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    Updated Covid vaccines prevented illness from latest variants -CDC
  • People embrace at the international arrivals gate at Beijing Capital International Airport after China lifted the coronavirus disease (COVID-19) quarantine requirement for inbound travellers in Beijing, China January 8, 2023. REUTERS/Thomas Peter
    China says peak Covid infections exceeded 7 million daily, deaths more than 4,000 daily

Related News

  • Democratic senators call for ban on marketing guns to kids
  • US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  • Classified documents found at former US Vice President Pence's home
  • US reiterates support for Finland, Sweden joining NATO
  • US, Germany poised to send tanks to Ukraine, answering Kyiv's pleas

Features

Snipe in flight. Photo: Enam Ul Haque

Baikka Beel: 'A world where snipe work late'

1h | Panorama
Photo: Noor-A-Alam

Pet cafes: Where love for food and animals cohabit

3h | Food
Illustration: TBS

How MFS is turbocharging national economy

6h | Thoughts
Now is the time to focus on FDI composition

Now is the time to focus on FDI composition

8h | Panorama

More Videos from TBS

Gold covered mummy discovered in Egypt

Gold covered mummy discovered in Egypt

51m | TBS World
Kajol’s road paintings bring change in Gafargaon

Kajol’s road paintings bring change in Gafargaon

1d | TBS Stories
Carew & Company witnessed a remarkable growth

Carew & Company witnessed a remarkable growth

1d | TBS Stories
Gavi may have to leave Camp Nou

Gavi may have to leave Camp Nou

18h | TBS SPORTS

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Four top bankers arrested in DSA case filed by S Alam group 
Bangladesh

Four top bankers arrested in DSA case filed by S Alam group 

3
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

4
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

5
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]